Base de dados : MEDLINE
Pesquisa : C10.228.140.079 [Categoria DeCS]
Referências encontradas : 4935 [refinar]
Mostrando: 1 .. 10   no formato [Detalhado]

página 1 de 494 ir para página                         

  1 / 4935 MEDLINE  
              next record last record
seleciona
para imprimir
Fotocópia
[PMID]:29205014
[Au] Autor:Sequeiros RB; Joronen K; Komar G; Koskinen SK
[Ti] Título:High intensity focused ultrasound (HIFU) in tumor therapy.
[So] Source:Duodecim;133(2):143-9, 2017.
[Is] ISSN:0012-7183
[Cp] País de publicação:Finland
[La] Idioma:eng
[Ab] Resumo:HIFU (high intensity focused ultrasound) is a method in which high-frequency ultrasound is focused on a tissue in order to achieve a thermal effect and the subsequent percutaneously ablation, or tissue modulation. HIFU is non-invasive and results in an immediate tissue destruction effect corresponding to surgery, either percutaneously or through body cavities. HIFU can be utilized in the treatment of both benign and malignant tumors. In neurological diseases, focused HIFU can be used in the treatment of disorders of the basal ganglia.
[Mh] Termos MeSH primário: Doenças dos Gânglios da Base/terapia
Ablação por Ultrassom Focalizado de Alta Intensidade
Neoplasias/terapia
[Mh] Termos MeSH secundário: Seres Humanos
[Pt] Tipo de publicação:JOURNAL ARTICLE; REVIEW
[Em] Mês de entrada:1801
[Cu] Atualização por classe:180115
[Lr] Data última revisão:
180115
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:171206
[St] Status:MEDLINE


  2 / 4935 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29236641
[Au] Autor:Eichler FS; Swoboda KJ; Hunt AL; Cestari DM; Rapalino O
[Ad] Endereço:From the Departments of Neurology (F.S.E., K.J.S., A.L.H.) and Radiology (O.R.), Massachusetts General Hospital, the Departments of Neurology (F.S.E., K.J.S., A.L.H.), Ophthalmology (D.M.C.), and Radiology (O.R.), Harvard Medical School, and the Department of Ophthalmology, Massachusetts Eye and Ear
[Ti] Título:Case 38-2017. A 20-Year-Old Woman with Seizures and Progressive Dystonia.
[So] Source:N Engl J Med;377(24):2376-2385, 2017 Dec 14.
[Is] ISSN:1533-4406
[Cp] País de publicação:United States
[La] Idioma:eng
[Mh] Termos MeSH primário: Doenças dos Gânglios da Base/diagnóstico
Distonia/etiologia
Proteínas de Membrana Transportadoras/genética
Mutação
Convulsões/etiologia
[Mh] Termos MeSH secundário: Doenças dos Gânglios da Base/complicações
Doenças dos Gânglios da Base/tratamento farmacológico
Doenças dos Gânglios da Base/genética
Biotina/uso terapêutico
Encéfalo/diagnóstico por imagem
Carbidopa/uso terapêutico
Diagnóstico Diferencial
Combinação de Medicamentos
Distonia/tratamento farmacológico
Feminino
Seres Humanos
Levodopa/uso terapêutico
Macula Lutea/patologia
Imagem por Ressonância Magnética
Erros Inatos do Metabolismo/diagnóstico
Nervo Óptico/patologia
Tiamina/uso terapêutico
Adulto Jovem
[Pt] Tipo de publicação:CASE REPORTS; CLINICAL CONFERENCE; JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Drug Combinations); 0 (Membrane Transport Proteins); 0 (SLC19A3 protein, human); 0 (carbidopa, levodopa drug combination); 46627O600J (Levodopa); 6SO6U10H04 (Biotin); MNX7R8C5VO (Carbidopa); X66NSO3N35 (Thiamine)
[Em] Mês de entrada:1712
[Cu] Atualização por classe:171220
[Lr] Data última revisão:
171220
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:171214
[St] Status:MEDLINE
[do] DOI:10.1056/NEJMcpc1706109


  3 / 4935 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28858444
[Au] Autor:Reeves S; Bertrand J; McLachlan E; D'Antonio F; Brownings S; Nair A; Greaves S; Smith A; Dunn JT; Marsden P; Kessler R; Uchida H; Taylor D; Howard R
[Ad] Endereço:Division of Psychiatry, University College London, 6th Floor, Maple House, 149 Tottenham Court Rd, London W1T 7NF. suzanne.reeves@ucl.ac.uk.
[Ti] Título:A Population Approach to Guide Amisulpride Dose Adjustments in Older Patients With Alzheimer's Disease.
[So] Source:J Clin Psychiatry;78(7):e844-e851, 2017 Jul.
[Is] ISSN:1555-2101
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:OBJECTIVE: We have previously reported high dopamine D2/3 receptor occupancies at low amisulpride concentrations in older people with Alzheimer's disease (AD), during off-label treatment of AD-related psychosis. This post hoc analysis explored pharmacokinetic (concentration) and pharmacodynamic (prolactin, D2/3 occupancy) contributions to symptom reduction and extrapyramidal side effects (EPS) to inform AD-specific dose adjustments. METHODS: Population pharmacokinetic-pharmacodynamic models were developed by combining pharmacokinetic data from a phase 1 study in 20 healthy older people with pharmacokinetic prolactin, [¹8F]fallypride D2/3 receptor imaging, and clinical outcome data from 28 older patients prescribed open amisulpride (25-75 mg/d) to treat AD-related psychosis. Model predictions were used to simulate dose-response and dose-EPS. RESULTS: Symptom reduction (delusions) was associated with amisulpride concentration (P = 1.3e-05) and D2/3 occupancy (P < .01, caudate, putamen, thalamus). Model predictions suggested that across concentrations of 40-100 ng/mL, and occupancies of 40% to 70% in the caudate and thalamus and 30% to 60% in the putamen, there was a 50% to 90% probability of response and < 30% probability of EPS. Simulations, based on concentration-delusions and concentration-EPS model outputs, showed that 50 mg/d of amisulpride was the appropriate dose to achieve this target range in those aged > 75 years; increasing the dose to 75 mg/d increased the risk of EPS, particularly in those aged > 85 years of low body weight. CONCLUSIONS: These findings argue strongly for the consideration of age- and weight-based dose adjustments in older patients with AD-related psychosis and indicate that 50 mg/d of amisulpride may be both the minimal clinically effective dose and, in those aged > 75 years, the maximally tolerated dose.
[Mh] Termos MeSH primário: Doença de Alzheimer/sangue
Doença de Alzheimer/tratamento farmacológico
Transtornos Psicóticos/sangue
Transtornos Psicóticos/tratamento farmacológico
Sulpirida/análogos & derivados
[Mh] Termos MeSH secundário: Idoso
Idoso de 80 Anos ou mais
Doença de Alzheimer/psicologia
Doenças dos Gânglios da Base/sangue
Doenças dos Gânglios da Base/induzido quimicamente
Doenças dos Gânglios da Base/prevenção & controle
Encéfalo/efeitos dos fármacos
Delusões/sangue
Delusões/tratamento farmacológico
Delusões/psicologia
Relação Dose-Resposta a Droga
Feminino
Seres Humanos
Masculino
Prolactina/sangue
Transtornos Psicóticos/psicologia
Receptores de Dopamina D2/efeitos dos fármacos
Receptores de Dopamina D3/efeitos dos fármacos
Valores de Referência
Fatores de Risco
Sulpirida/administração & dosagem
Sulpirida/efeitos adversos
Sulpirida/farmacocinética
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Receptors, Dopamine D2); 0 (Receptors, Dopamine D3); 7MNE9M8287 (Sulpiride); 9002-62-4 (Prolactin); AA0G3TW31W (sultopride)
[Em] Mês de entrada:1709
[Cu] Atualização por classe:170921
[Lr] Data última revisão:
170921
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170901
[St] Status:MEDLINE


  4 / 4935 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28754841
[Au] Autor:Smith R; Schöll M; Widner H; van Westen D; Svenningsson P; Hägerström D; Ohlsson T; Jögi J; Nilsson C; Hansson O
[Ad] Endereço:From the Departments of Neurology (R.S., H.W., C.N.), Clinical Neurophysiology (D.H.), Radiation Physics (T.O.), and Clinical Physiology and Nuclear Medicine (J.J.), Skåne University Hospital (D.v.W.), Lund; Clinical Memory Research Unit (R.S., M.S., C.N., O.H.), Department of Clinical Sciences (D.v
[Ti] Título:In vivo retention of F-AV-1451 in corticobasal syndrome.
[So] Source:Neurology;89(8):845-853, 2017 Aug 22.
[Is] ISSN:1526-632X
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:OBJECTIVE: To study the usefulness of F-AV-1451 PET in patients with corticobasal syndrome (CBS). METHODS: We recruited 8 patients with CBS, 17 controls, 31 patients with Alzheimer disease (AD), and 11 patients with progressive supranuclear palsy (PSP) from the Swedish BioFINDER study. All patients underwent clinical assessment, F-AV-1451 PET, MRI, and quantification of ß-amyloid pathology. A subset of participants also underwent F-FDG-PET. RESULTS: In the 8 patients with CBS, 6 had imaging findings compatible with the corticobasal degeneration pathology and 2 with typical AD pathology. In the 6 patients with CBS without typical AD pathology, there were substantial retentions of F-AV-1451 in the motor cortex, corticospinal tract, and basal ganglia contralateral to the most affected body side. These patients could be clearly distinguished from patients with AD dementia or PSP using F-AV-1451. However, cortical atrophy was more widespread than the cortical retention of F-AV1451 in these CBS cases, and cortical AV-1451 uptake did not correlate with cortical thickness or glucose hypometabolism. These results are in sharp contrast to AD dementia, where F-AV-1451 retention was more widespread than cortical atrophy, and correlated well with cortical thickness and hypometabolism. CONCLUSIONS: Patients with CBS without typical AD pathology exhibited AV-1451 retention in the motor cortex, corticospinal tract, and basal ganglia contralateral to the affected body side, clearly different from controls and patients with AD dementia or PSP. However, cortical atrophy measured with MRI and decreased F-fluorodeoxyglucose uptake were more widespread than F-AV-1451 uptake and probably represent earlier, yet less specific, markers of CBS. CLASSIFICATION OF EVIDENCE: This study provides Class III evidence that F-AV-1451 PET distinguishes between CBS and AD or PSP.
[Mh] Termos MeSH primário: Doenças dos Gânglios da Base/diagnóstico por imagem
Encéfalo/diagnóstico por imagem
Carbolinas/farmacocinética
Tomografia por Emissão de Pósitrons
Compostos Radiofarmacêuticos/farmacocinética
[Mh] Termos MeSH secundário: Idoso
Doença de Alzheimer/diagnóstico por imagem
Doença de Alzheimer/metabolismo
Doenças dos Gânglios da Base/metabolismo
Encéfalo/metabolismo
Mapeamento Encefálico
Diagnóstico Diferencial
Seres Humanos
Imagem por Ressonância Magnética
Meia-Idade
Tratos Piramidais/diagnóstico por imagem
Tratos Piramidais/metabolismo
Paralisia Supranuclear Progressiva/diagnóstico por imagem
Paralisia Supranuclear Progressiva/metabolismo
Suécia
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole); 0 (Carbolines); 0 (Radiopharmaceuticals)
[Em] Mês de entrada:1708
[Cu] Atualização por classe:170910
[Lr] Data última revisão:
170910
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:170730
[St] Status:MEDLINE
[do] DOI:10.1212/WNL.0000000000004264


  5 / 4935 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28605144
[Au] Autor:de Carvalho LM; Ngoumou G; Park JW; Ehmke N; Deigendesch N; Kitabayashi N; Melki I; Souza FFL; Tzschach A; Nogueira-Barbosa MH; Ferriani V; Louzada-Junior P; Marques W; Lourenço CM; Horn D; Kallinich T; Stenzel W; Hur S; Rice GI; Crow YJ
[Ad] Endereço:Ribeirão Preto Medical School, University of São Paulo, São Paulo, Brazil.
[Ti] Título:Musculoskeletal Disease in MDA5-Related Type I Interferonopathy: A Mendelian Mimic of Jaccoud's Arthropathy.
[So] Source:Arthritis Rheumatol;69(10):2081-2091, 2017 Oct.
[Is] ISSN:2326-5205
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:OBJECTIVE: To define the molecular basis of a multisystem phenotype with progressive musculoskeletal disease of the hands and feet, including camptodactyly, subluxation, and tendon rupture, reminiscent of Jaccoud's arthropathy. METHODS: We identified 2 families segregating an autosomal-dominant phenotype encompassing musculoskeletal disease and variable additional features, including psoriasis, dental abnormalities, cardiac valve involvement, glaucoma, and basal ganglia calcification. We measured the expression of interferon (IFN)-stimulated genes in the peripheral blood and skin, and undertook targeted Sanger sequencing of the IFIH1 gene encoding the cytosolic double-stranded RNA (dsRNA) sensor melanoma differentiation-associated protein 5 (MDA-5). We also assessed the functional consequences of IFIH1 gene variants using an in vitro IFNß reporter assay in HEK 293T cells. RESULTS: We recorded an up-regulation of type I IFN-induced gene transcripts in all 5 patients tested and identified a heterozygous gain-of-function mutation in IFIH1 in each family, resulting in different substitutions of the threonine residue at position 331 of MDA-5. Both of these variants were associated with increased IFNß expression in the absence of exogenous dsRNA ligand, consistent with constitutive activation of MDA-5. CONCLUSION: These cases highlight the significant musculoskeletal involvement that can be associated with mutations in MDA-5, and emphasize the value of testing for up-regulation of IFN signaling as a marker of the underlying molecular lesion. Our data indicate that both Singleton-Merten syndrome and neuroinflammation described in the context of MDA-5 gain-of-function constitute part of the same type I interferonopathy disease spectrum, and provide possible novel insight into the pathology of Jaccoud's arthropathy.
[Mh] Termos MeSH primário: Doenças da Aorta/genética
Doenças dos Gânglios da Base/genética
Calcinose/genética
Hipoplasia do Esmalte Dentário/genética
Glaucoma/genética
Doenças das Valvas Cardíacas/genética
Helicase IFIH1 Induzida por Interferon/genética
Metacarpo/anormalidades
Doenças Musculares/genética
Doenças Musculoesqueléticas/genética
Odontodisplasia/genética
Osteoporose/genética
Psoríase/genética
Calcificação Vascular/genética
[Mh] Termos MeSH secundário: Adolescente
Adulto
Criança
Células HEK293
Heterozigoto
Seres Humanos
Meia-Idade
Mutação
Síndrome
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
EC 3.6.1.- (IFIH1 protein, human); EC 3.6.4.13 (Interferon-Induced Helicase, IFIH1)
[Em] Mês de entrada:1710
[Cu] Atualização por classe:171010
[Lr] Data última revisão:
171010
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:170613
[St] Status:MEDLINE
[do] DOI:10.1002/art.40179


  6 / 4935 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28445282
[Au] Autor:Niu B; Zou Z; Shen Y; Cao B
[Ad] Endereço:Department of Neurology, General Hospital of Jinan Military Region, Jinan, Shandong Province, China.
[Ti] Título:A case report of Sjögren syndrome manifesting bilateral basal ganglia lesions.
[So] Source:Medicine (Baltimore);96(17):e6715, 2017 Apr.
[Is] ISSN:1536-5964
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:RATIONALE: Peripheral neurological complications in primary Sjögren's syndrome (pSS) seem the most common, however the involvement of central nervous system (CNS) remains unclear. While abnormalities in pSS revealed by brain magnetic resonance imaging (MRI) are usually small discrete hyperintense areas in the white matter on T2-FLAIR weighted MRI, massive brain lesions have been rarely reported, particularly in bilateral basal ganglia. PATIENT CONCERNS: A 51-year-old woman exhibited dizziness, slurred speech and hemiplegia as a manifestation of pSS. Brain MRI revealed bilateral and symmetrical lesions extending into the basal ganglia, corona radiata and corpus callosum. DIAGNOSES: Primary Sjögren's syndrome was diagnosed on the basis of clinical features, abnormal Schirmer's test and tear break-up time (BUT) findings, high levels of anti-Sjögren's-syndrome-related antigen A (anti-SSA) (Ro) and anti-Sjögren's-syndrome-related antigen B (anti-SSB) (La) antibodies, and positive labial minor salivary gland biopsy results. INTERVENTIONS: She was treated with intravenous methylprednisolone and discharged on oral steroid therapy of prednisolone acetate. OUTCOMES: The patient had an excellent response to steroid therapy. LESSONS: The present case suggests that symmetry bilateral lesions can occur as a symptom of pSS, which could be induced by an autoimmune mechanism.
[Mh] Termos MeSH primário: Doenças dos Gânglios da Base/diagnóstico por imagem
Gânglios da Base/diagnóstico por imagem
Imagem por Ressonância Magnética
Síndrome de Sjogren/diagnóstico por imagem
[Mh] Termos MeSH secundário: Doenças dos Gânglios da Base/tratamento farmacológico
Doenças dos Gânglios da Base/imunologia
Doenças dos Gânglios da Base/patologia
Diagnóstico Diferencial
Feminino
Seres Humanos
Meia-Idade
Síndrome de Sjogren/tratamento farmacológico
Síndrome de Sjogren/imunologia
Síndrome de Sjogren/patologia
[Pt] Tipo de publicação:CASE REPORTS; JOURNAL ARTICLE
[Em] Mês de entrada:1706
[Cu] Atualização por classe:170601
[Lr] Data última revisão:
170601
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:170427
[St] Status:MEDLINE
[do] DOI:10.1097/MD.0000000000006715


  7 / 4935 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:28437058
[Au] Autor:Holder SD; Edmunds AL; Morgan S
[Ad] Endereço:Baylor Family Medicine Residency at Garland, 601 Clara Barton Blvd. Suite 340, Garland, TX 75042.
[Ti] Título:Psychotic and Bipolar Disorders: Antipsychotic Drugs.
[So] Source:FP Essent;455:23-29, 2017 Apr.
[Is] ISSN:2159-3000
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Antipsychotic drugs block dopamine receptors and are used to manage psychosis as well as other mental illnesses that may or may not have psychotic features, such as bipolar disorders and major depressive disorder. First-generation antipsychotic drugs are more likely to cause adverse effects such as extrapyramidal symptoms and tardive dyskinesia. Adverse effects of second-generation antipsychotic drugs typically are related to metabolic abnormalities such as weight gain, abnormal blood glucose levels, and elevated lipid levels. Neuroleptic malignant syndrome is a rare but serious adverse effect of antipsychotic drugs that causes mental status changes, hyperthermia, and generalized rigidity. Timely diagnosis is essential due to a high risk of related morbidities if the syndrome remains untreated. Some adverse effects of antipsychotics can be identified and managed so that patients can continue beneficial therapy while minimizing the physiologic consequences. Patients taking antipsychotic drugs should be monitored regularly for adverse effects. Antipsychotics are also associated with potential drug interactions, the most lethal being prolongation of the QT interval, which can lead to fatal arrhythmias. Antipsychotic drugs can be used in special populations, such as pregnant women, children, and elderly patients, per recommendation from a mental health subspecialist.
[Mh] Termos MeSH primário: Antipsicóticos/uso terapêutico
Transtorno Bipolar/tratamento farmacológico
Transtorno Depressivo Maior/tratamento farmacológico
Transtornos Psicóticos/tratamento farmacológico
Esquizofrenia/tratamento farmacológico
[Mh] Termos MeSH secundário: Doenças dos Gânglios da Base/induzido quimicamente
Transtorno Bipolar/psicologia
Aleitamento Materno
Transtorno Depressivo Maior/psicologia
Interações Medicamentosas
Dislipidemias/induzido quimicamente
Feminino
Seres Humanos
Hiperglicemia/induzido quimicamente
Síndrome do QT Longo/induzido quimicamente
Masculino
Síndrome Maligna Neuroléptica/etiologia
Gravidez
Complicações na Gravidez/tratamento farmacológico
Transtornos Psicóticos/psicologia
Psicologia do Esquizofrênico
Discinesia Tardia/induzido quimicamente
Ganho de Peso
[Pt] Tipo de publicação:JOURNAL ARTICLE; REVIEW
[Nm] Nome de substância:
0 (Antipsychotic Agents)
[Em] Mês de entrada:1706
[Cu] Atualização por classe:170615
[Lr] Data última revisão:
170615
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170425
[St] Status:MEDLINE


  8 / 4935 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28408259
[Au] Autor:Fu W; Ju Y; Zhang S; You C
[Ad] Endereço:Department of Neurosurgery, West China Hospital of Sichuan University, Chengdu, Sichuan, China.
[Ti] Título:Pediatric Basal Ganglia Region Tumors: Clinical and Radiologic Features Correlated with Histopathologic Findings.
[So] Source:World Neurosurg;103:504-516, 2017 Jul.
[Is] ISSN:1878-8769
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:PURPOSE: To summarize the clinical and radiologic features of pediatric basal ganglia region tumors (PBGRT) in correlation with their histopathologic findings to reduce inappropriate surgery and identify tumors that can benefit from maximal safe resection. METHODS: The records of 35 children with PBGRT treated in our hospital from December 2011 to December 2015 were analyzed retrospectively. The clinical and radiologic features of these tumors were summarized and correlated with their histopathologic diagnosis. RESULTS: Our series included 15 astrocytomas and 11 germ cell tumors (GCTs). Basal ganglia astrocytomas were characterized by various clinical presentations and an ill-circumscribed mass with the involvement of surrounding structures on neuroimaging and mostly occurred in the first decade of life (n = 10; 66.7%). Basal ganglia GCT mostly occurred in the second decade of life (n = 8; 72.7%) with hemiparesis as the most common symptom (n = 9; 81.8%). The tumors were located predominantly in the caput of caudate nucleus (n = 8; 72.7%) with hemiatrophy as the typical sign (n = 8; 72.7%). Occasionally, other tumors also could occur in this region, including primitive neuroectodermal tumor (n = 1), atypical teratoid/rhabdoid tumor (n = 1), anaplastic ependymoma (n = 1), lymphoma (n = 1), extraventricular neurocytoma (n = 1), gangliogliomas (n = 2), oligodendroglioma (n = 1), and dysembryoplastic neuroepithelial tumor (n = 1). CONCLUSIONS: Astrocytoma and GCT are the most common PBGRTs. Low-grade astrocytomas could benefit from maximal surgical resection, whereas GCTs merit neoadjuvant chemoradiation therapy followed by second-look surgery. We advocate routine testing of tumor markers and analysis of their clinical and radiologic features to optimize the therapeutic strategy.
[Mh] Termos MeSH primário: Astrocitoma/terapia
Doenças dos Gânglios da Base/terapia
Biomarcadores Tumorais/metabolismo
Neoplasias Encefálicas/terapia
Quimiorradioterapia
Terapia Neoadjuvante
Neoplasias Embrionárias de Células Germinativas/terapia
Procedimentos Neurocirúrgicos
[Mh] Termos MeSH secundário: Adolescente
Astrocitoma/complicações
Astrocitoma/diagnóstico por imagem
Astrocitoma/metabolismo
Doenças dos Gânglios da Base/complicações
Doenças dos Gânglios da Base/diagnóstico por imagem
Doenças dos Gânglios da Base/metabolismo
Neoplasias Encefálicas/complicações
Neoplasias Encefálicas/diagnóstico por imagem
Neoplasias Encefálicas/metabolismo
Núcleo Caudado/diagnóstico por imagem
Núcleo Caudado/cirurgia
Criança
Pré-Escolar
Tontura/etiologia
Ependimoma/complicações
Ependimoma/diagnóstico por imagem
Ependimoma/metabolismo
Ependimoma/terapia
Feminino
Ganglioglioma/complicações
Ganglioglioma/diagnóstico por imagem
Ganglioglioma/metabolismo
Ganglioglioma/terapia
Cefaleia/etiologia
Seres Humanos
Lactente
Linfoma/complicações
Linfoma/diagnóstico por imagem
Linfoma/metabolismo
Linfoma/terapia
Masculino
Técnicas de Diagnóstico Molecular
Neoplasias Embrionárias de Células Germinativas/complicações
Neoplasias Embrionárias de Células Germinativas/diagnóstico por imagem
Neoplasias Embrionárias de Células Germinativas/metabolismo
Neoplasias Neuroepiteliomatosas/complicações
Neoplasias Neuroepiteliomatosas/diagnóstico por imagem
Neoplasias Neuroepiteliomatosas/terapia
Neurocitoma/complicações
Neurocitoma/diagnóstico por imagem
Neurocitoma/metabolismo
Neurocitoma/terapia
Tumores Neuroectodérmicos Primitivos/complicações
Tumores Neuroectodérmicos Primitivos/diagnóstico por imagem
Tumores Neuroectodérmicos Primitivos/metabolismo
Tumores Neuroectodérmicos Primitivos/terapia
Oligodendroglioma/complicações
Oligodendroglioma/diagnóstico por imagem
Oligodendroglioma/metabolismo
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Biomarkers, Tumor)
[Em] Mês de entrada:1709
[Cu] Atualização por classe:170925
[Lr] Data última revisão:
170925
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170415
[St] Status:MEDLINE


  9 / 4935 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28374697
[Au] Autor:Tiganov AS; Panteleeva GP; Abramova LI; Bologov PV; Kananovich PS; Omel'chenko MA; Nikiforova IY
[Ad] Endereço:Mental Health Research Center, Moscow, Russia.
[Ti] Título:[A differential approach to the improvement of prevention and correction of neuroleptic side extrapyramidal disorders with pantogam activ in patients with schizophrenia].
[Ti] Título:Differentsirovannyi podkhod k usovershenstvovaniyu metodov preduprezhdeniya i korrektsii neirolepticheskikh pobochnykh ekstrapiramidnykh rasstroistv preparatom pantogam aktiv u bol'nykh shizofreniei..
[So] Source:Zh Nevrol Psikhiatr Im S S Korsakova;117(2):72-80, 2017.
[Is] ISSN:1997-7298
[Cp] País de publicação:Russia (Federation)
[La] Idioma:rus
[Ab] Resumo:AIM: To assess the efficacy and safety of pantogam active (PA) in prevention and correction of neurological side-effects during the course neuroleptic treatment of acute endogenous psychoses. MATERIAL AND METHODS: Eighty schizophrenic patients (mean age 33 years) with acute psychosis were examined. All patients received 28-day course treatment with typical and atypical neuroleptics. Two equal groups were studied: patients of the first group were treated with trihexyphenidyl (THP) in dose of 0,002-0,012 mg and patients of the second group received in addition PA in dose 0,9 mg/day. Clinical-observation, psychometric scales (PANSS, CGI-S, UKU) were administered at baseline and in 1st,3rd,7th, 14th, 21st, 28st day. RESULTS: PA in the combination with THP improved tolerability to neuroleptic therapy in whole and exerted the better correction effect on neuroleptic extrapyramidal disorders (EPD) compared to THP monotherapy. The number of patients with ERD was reduced by 1.5 times and prevention of EPD was observed 3 times more frequent in the group treated with PA. In the THP group, other adverse effects (AE) were 1,7 times more frequent and the total AE score was 2,5 times greater compared to the PA group (131 vs 50). Correction and preventive effects of the combined treatment on the clinically severe symptoms of EPD (akathisia, muscle dystonia) were more frequent in patients treated with typical neuroleptics. A less amount of THP (by 1,2 times) was used to stop EPD in the PA group. CONCLUSION: PA in the combination with THP has demonstrated the clear neuroprotective effect on the development, frequency and clinical presentations of neurological side-effects. The РА can be recommended as a drug of choice for correction and prevention of neuroleptic side-effects, it promotes their tolerability and improves quality of life during the course treatment.
[Mh] Termos MeSH primário: Antipsicóticos/efeitos adversos
Doenças dos Gânglios da Base/induzido quimicamente
Doenças dos Gânglios da Base/tratamento farmacológico
Nootrópicos/uso terapêutico
Ácido Pantotênico/análogos & derivados
Esquizofrenia/tratamento farmacológico
Triexifenidil/efeitos adversos
Ácido gama-Aminobutírico/análogos & derivados
[Mh] Termos MeSH secundário: Adolescente
Adulto
Antipsicóticos/uso terapêutico
Doenças dos Gânglios da Base/prevenção & controle
Quimioterapia Combinada
Feminino
Seres Humanos
Masculino
Meia-Idade
Ácido Pantotênico/uso terapêutico
Qualidade de Vida
Resultado do Tratamento
Triexifenidil/uso terapêutico
Adulto Jovem
Ácido gama-Aminobutírico/uso terapêutico
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Antipsychotic Agents); 0 (Nootropic Agents); 1977-33-9 (pantogab); 19F5HK2737 (Pantothenic Acid); 56-12-2 (gamma-Aminobutyric Acid); 6RC5V8B7PO (Trihexyphenidyl)
[Em] Mês de entrada:1708
[Cu] Atualização por classe:170810
[Lr] Data última revisão:
170810
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170405
[St] Status:MEDLINE
[do] DOI:10.17116/jnevro20171172172-80


  10 / 4935 MEDLINE  
              first record previous record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28296742
[Au] Autor:Song CY; Zhao ZX; Li W; Sun CC; Liu YM
[Ad] Endereço:Department of Neurology, Qilu Hospital of Shandong University, Jinan, China.
[Ti] Título:Pseudohypoparathyroidism with basal ganglia calcification: A case report of rare cause of reversible parkinsonism.
[So] Source:Medicine (Baltimore);96(11):e6312, 2017 Mar.
[Is] ISSN:1536-5964
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:RATIONALE: Parkinsonism can be secondary to many internal diseases, in some certain conditions, it seems that the clinical manifestations of parkinsonism presenting reversible. We report a case of patient with parkinsonism secondary to pseudohypoparathyroidism, who improved markedly after the supplement of serum calcium. PATIENT CONCERNS AND DIAGNOSES: A 52-year-old woman with acute parkinsonism was diagnosed as pseudohypoparathyroidism after the conducting of brain computed tomography, laboratory examinations, and gene detection. The son of the patient was also examined and was diagnosed as pseudohypoparathyroidism, who had ever complained of the history of epilepsy. The clinical manifestations of parkinsonism of the patient was reevaluated after the supplement of serum calcium according to the diagnosis. INTERVENTIONS AND OUTCOMES: The brain computed tomography revealed the basal ganglia calcification of the patient, accompanying by serum hypocalcemia and hyperphosphatemia. Loss of function mutation also confirmed the diagnosis. Five days after the therapy targeting at correction of serum hypocalcemia, the patient improved greatly in dyskinesia. LESSONS: This study reported a patient presenting as acute reversible parkinsonism, who was finally diagnosed as pseudohypoparathyroidism. It indicated us that secondary parkinsonism should be carefully differentiated for its dramatic treatment effect. And the family history of seizures might be an indicator for the consideration of pseudohypoparathyroidism.
[Mh] Termos MeSH primário: Transtornos Parkinsonianos/etnologia
Pseudo-Hipoparatireoidismo/complicações
[Mh] Termos MeSH secundário: Doenças dos Gânglios da Base/complicações
Calcinose/complicações
Cálcio/uso terapêutico
Feminino
Seres Humanos
Meia-Idade
Pseudo-Hipoparatireoidismo/tratamento farmacológico
[Pt] Tipo de publicação:CASE REPORTS; JOURNAL ARTICLE
[Nm] Nome de substância:
SY7Q814VUP (Calcium)
[Em] Mês de entrada:1703
[Cu] Atualização por classe:170403
[Lr] Data última revisão:
170403
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:170316
[St] Status:MEDLINE
[do] DOI:10.1097/MD.0000000000006312



página 1 de 494 ir para página                         
   


Refinar a pesquisa
  Base de dados : MEDLINE Formulário avançado   

    Pesquisar no campo  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/OPAS/OMS - Centro Latino-Americano e do Caribe de Informação em Ciências da Saúde